Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI

Civil Hospices of Lyon

Status: Completed

Conditions: Antibiotic Reaction; Bone and Joint Infection

Treatments: Other: Description of use of ceftaroline and ceftobiprole

Study type: Observational

Funder types: Other

Identifiers

NCT04409769

20-157

Details and patient eligibility

About

Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option.

Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole

Exclusion criteria

Trial design

22 participants in 1 patient group

Description of use of ceftaroline and ceftobiprole

Description:

description of patients and their PJI/BJI,conditions of use, adverse event

Treatment:

Other: Description of use of ceftaroline and ceftobiprole